Sulforaphane in Treating Patients With Recurrent Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: the patientdlulnradiationct
  Phrases that lowered it: prostateparticipantspsavaluereference
• Sponsor's past termination rate: 46.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 56.8% (lowers risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 32 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 6.2% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 269 (raises risk) · Drug's FDA history
• Sex: male (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer NCT03686683 · started 2018 · scored riskier than 45% of active trials completed
• Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone NCT03304418 · started 2018 · scored riskier than 79% of active trials completed
• Herbal Therapy for Treatment of Recurrent Prostate Cancer NCT00669656 · started 2008 · scored riskier than 99% of active trials completed
• A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones NCT05133440 · started 2021 · scored riskier than 50% of active trials completed
• Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer NCT03503344 · started 2019 · scored riskier than 70% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.